Skip to main content
U.S. flag

An official website of the United States government

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Search help
31 results
  1. Langerhans Cell Histiocytosis Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf 
    https://www.ncbi.nlm.nih.gov/books/NBK65799
    ... joins a group of other pediatric entities with activating BRAF mutations, including select nonmalignant conditions (e.g., benign nevi) [ ... Quispel W, Badalian-Very G, et al.: Somatic activating ARAF mutations in Langerhans cell ... somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in ...
  2. Childhood Astrocytomas Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf 
    https://www.ncbi.nlm.nih.gov/books/NBK65944
    ... Dougherty MJ, Santi M, Brose MS, et al.: Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. ...
  3. Thyroid Cancer Treatment (Adult) (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf 
    https://www.ncbi.nlm.nih.gov/books/NBK65719
    ... estimated 25% of anaplastic thyroid cancers harbor an activating BRAF (V600E) mutation.[ 8 ] Evidence (dabrafenib and trametinib): A phase II ...
  4. NLM Informatics Training Conference 2012 
    https://www.nlm.nih.gov/ep/trainingconf2012.html
    ... improve survival. The most promising example is the activating V600E/K mutation in the protein kinase BRAF. This mutation is present in ~50% of cutaneous ...
  5. pdf2012 NLM Training Conference 
    https://www.nlm.nih.gov/.../TC2012TrainingConferenceBook.pdf
    ... improve survival. The most promising example is the activating V600E/K mutation in the protein kinase BRAF. This mutation is present in ~50% of cutaneous ...
  6. NLM Digital Collections - Enrichment strategies for clinical trials to support determination of effectiveness of human .... 
    Publication: Silver Spring, MD : Center for Drug Evaluation and Research, March 2019
    resource.nlm.nih.gov/101760015
    ... 40% to 60% of all melanomas carry this activating mutation. In a study of 49 patients with melanoma, 11 of 16 patients with BRAF V600E mutation who received vemurafenib had a tumor ...
  7. Gastrointestinal stromal tumor: MedlinePlus Genetics 
    https://medlineplus.gov/.../condition/gastrointestinal-stromal-tumor
    ... Dematteo RP, Besmer P, Antonescu CR. Novel V600E BRAF mutations in imatinib-naive ... activating mutations in gastrointestinal stromal tumors. Science. 2003 Jan ...
  8. PIK3CA-Related Segmental Overgrowth - GeneReviews® - NCBI Bookshelf 
    https://www.ncbi.nlm.nih.gov/books/NBK153722
    ... Yamamoto GL, Kozakewich HP, Warman ML. Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. Am J Hum ... overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. Nat Genet. 2012; 44 :928–33. [ ...
  9. Noonan Syndrome - GeneReviews® - NCBI Bookshelf 
    https://www.ncbi.nlm.nih.gov/books/NBK1124
    ... Vogelstein B, Meyerson M, Sellers WR, Neel BG. Activating mutations of the Noonan syndrome-associated SHP2/PTPN11 gene ... Cavé H, Gelb BD, Neel BG, Tartaglia M. Activating mutations affecting the Dbl homology domain of SOS2 cause ...
  10. Colon Cancer Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf 
    https://www.ncbi.nlm.nih.gov/books/NBK65858
    ... harbor wild types of KRAS (i.e., lack activating mutations at codon 12 or 13 of the KRAS ... KRAS exon 2 status for other KRAS and BRAF mutations.[ 83 ][ Level of evidence: 3iiiA ] Of the 620 ...
previous · 1 · 2 · 3 · next